D

Dayton Center for Neurological Disorders | Centerville, OH

Research site

(Unclaimed)

Location

1975 Miamisburg Centerville Road, Centerville, Ohio, United States of America

Site insights

Top conditions

Top treatments

Tolebrutinib

Simufilam

ABP-450

Safinamide

Buntanetap

Galcanezumab

Droxidopa

Ofatumumab

Pimavanserin

Florbetapir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 21 total trials

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...

Enrolling

Secondary Progressive Multiple Sclerosis

Relapsing Multiple Sclerosis

Drug: Teriflunomide

Drug: Placebo

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis (NIMBLE)

This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with g...

Enrolling

Generalized Myasthenia Gravis

Drug: Pozelimab

Drug: Pozelimab + Cemdisiran

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling

Multiple Sclerosis

Drug: Activated charcoal

Drug: Cholestyramine

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab (FILIOS)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosag...

Enrolling

Relapsing Multiple Sclerosis (RMS)

Biological: Ofatumumab approved dose

Biological: Ofatumumab new dose